Data / Form D filings / Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.: Form D filings
Apellis Pharmaceuticals, Inc., a pharmaceuticals company in Crestwood, KY, filed 11 Form D notices with the SEC between 2010 and 2017. The latest, on August 17, 2017, reports $20 million sold of a $60.1 million offering to 16 investors.
Find out what Apellis Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6400 WESTWIND WAY, SUITE A, Crestwood, KY, 40014
- Phone
- (502) 241-4114
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1492422
The full lists. Form D filings in Kentucky: 216 rows, $10.80, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 17, 2017 | New notice | $60,099,974 | $20,033,322 | $40,066,652 | 16 | Aug 7, 2017 | sec.gov |
| Feb 8, 2016 | New notice | $47,135,951 | $47,135,951 | $0 | 7 | Dec 24, 2015 | sec.gov |
| Jan 6, 2016 | New notice | $32,135,952 | $32,135,952 | $0 | 6 | Dec 24, 2015 | sec.gov |
| Jun 9, 2015 | Amendment | $17,732,150 | $17,732,150 | $0 | 1 | Dec 5, 2014 | sec.gov |
| Dec 17, 2014 | New notice | $21,500,000 | $6,000,000 | $15,500,000 | 1 | Dec 5, 2014 | sec.gov |
| Aug 27, 2014 | Amendment | $24,000,000 | $17,842,487 | $6,157,513 | 25 | Jul 30, 2013 | sec.gov |
| Aug 5, 2013 | New notice | $8,000,000 | $6,000,000 | $2,000,000 | 1 | Jul 30, 2013 | sec.gov |
| Jul 25, 2012 | New notice | $3,000,000 | $692,995 | $2,307,005 | 9 | Jul 18, 2012 | sec.gov |
| Jun 20, 2011 | Amendment | $4,213,000 | $2,967,500 | $1,245,500 | 15 | May 20, 2011 | sec.gov |
| Jun 1, 2011 | New notice | $4,213,000 | $1,688,500 | $2,524,500 | 11 | May 20, 2011 | sec.gov |
| May 21, 2010 | New notice | $6,000,000 | $1,700,000 | $4,300,000 | 6 | May 21, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Bihua Sinclair Chen | Director | |
| Steven Sinclair Axon | Executive Officer | |
| Alec Sinclair Machiels | Director | |
| Stephanie Sinclair O'Brien | Director | |
| Robert Sinclair Adelman | Director | |
| Nicole Sinclair Perry | Executive Officer | |
| Maha Sinclair Katabi | Director | |
| Gerald Sinclair Chan | Director | |
| A. Sinclair Dunlop | Director | |
| Daniel Sinclair Geffken | Executive Officer | |
| Cedric Francois | Executive Officer, Director | |
| Pascal Deschatelets | Executive Officer | |
| David Sinclair Watson | Executive Officer | |
| Robert Sinclair Kim | Executive Officer |
Every Form D from the week of Aug 14, 2017 · All recent filings in Kentucky · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Apellis Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.